Latest NicVAX Stories
By Anne Harding NEW YORK (Reuters Health) - Research with a new nicotine vaccine shows that the vaccine is safe and well tolerated, with higher doses producing a greater rate of abstinence.
A University of Minnesota study indicates that the nicotine vaccine NicVax, which is now being tested in humans, appears safe, well-tolerated, and a potentially effective method for helping smokers kick the habit.
Swiss researchers have reported initial positive results with an experimental nicotine vaccine that might help smokers quit.
- A transitional zone between two communities containing the characteristic species of each.